In terms of combination therapy, the combination of ibrutinib and R-CHOP can significantly improve the efficacy of R/R DLBCL, and the effectiveness of the GCB subtype is still inferior to that of the ABC subtype [318]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.